Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Dyax Corp. (DYAX) PT Raised to $25 at Leerink Partners
April 1, 2015 8:37 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and boosted his price target on Dyax Corp. (NASDAQ: DYAX) to $25.00 (from $16.00) after the company announced data from its Phase Ib study of DX-2930 in Hereditary Angioedema (HAE).
Schwartz commented, "The study, which... More
Dyax (DYAX) PT Raised to $35 at Wedbush
April 1, 2015 7:02 AM EDTWedbush analyst Heather Behanna reiterated a Outperform rating and boosted her price target on Dyax Corp. (NASDAQ: DYAX) to $35.00 (from $18.00).
Behanna commented, "Small numbers, but data suggest DX-2930 could represent the new gold standard for HAE prophylaxis. Dyax reported its Phase Ib data on... More
Dyax Corp. (DYAX) PT Lifted to $31 at Jefferies
April 1, 2015 6:54 AM EDTJefferies analyst Biren Amin reiterated a Buy rating and boosted his price target on Dyax Corp. (NASDAQ: DYAX) to $31.00 (from $18.00) saying DX-2930 has potential as next standard of care in HAE.
DYAX reported detailed data from the PIb trial evaluating DX-2930 in patients w/... More
Dyax Corp. (DYAX) PT Raised to $30 at Needham & Company
April 1, 2015 6:18 AM EDTNeedham & Company analyst Serge Belanger reiterated a Buy rating and boosted his price target on Dyax Corp. (NASDAQ: DYAX) to $30.00 (from $19.00) following positive ph 1b results of DX-2930.
Belanger commented, "Strong positive results from a ph 1b study evaluating DX-2930 in HAE patients... More
Dyax Corp (DYAX) DX-2930 Looks Great, Says RBC
March 31, 2015 4:56 PM EDTRBC Capital analyst Michael J. Yee commented on Dyax Corp (NASDAQ: DYAX) following the release of positive DX-2930 data in HAE. In his view, data "looks great" and is above expectations.
Yee explained, "Dyax reported Phase IB data for DX-2930. Efficacy and... More
Dyax Corp (DYAX) Announces Positive Results from Phase 1b Trial of DX-2930 and Fast Track Designation
March 31, 2015 4:04 PM EDTDyax Corp. (NASDAQ: DYAX) today announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.
The ongoing Phase 1b study is a multi-center, randomized, double-blind, placebo-controlled, multiple-ascending dose study designed to assess the safety, tolerability and pharmacokinetics of... More
